April 20, 2006 – In a deal with an unusual structure, Dynavax put its immunostimulatory program into a new company called Symphony Dynamo with $50 million of new cash; MedImmune took a 12% haircut after Synagis, its main revenue driver, was $9 million light in Q1; Integra LifeSciences will pay $101 million in cash to buy Miltex, also a maker of surgical equipment; Alteon will buy HaptoGuard for $8.8 million in stock; Schering-Plough won fast track for its anti-blood-clot drug; the FDA accepted its application for Rasilez, a blood pressure drug from Novartis; and Pozen has agreed with the FDA on a special protocol assessment for a Phase III trial of its arthritis drug. The Centient Biotech 200™ was 3.5 points higher at 3826.72, a rise of .09%. More details...
